SecurityRNET / RigNet, Inc. (766582100)
IndustryCommunications Services, Not Elsewhere Classified
Common Shares Outstanding19,363,507 shares (as of 2018-03-31)
Total Insiders22
Total Directors8
Total Officers14

Stock Insider Trading (from SEC Form 4)

RigNet, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

RNET / RigNet, Inc. insiders include Browning James H, Sullivan Brendan HILBERT JAY T, Carter Benjamin Andrew, PICKETT STEVEN EDWARD, Jimmerson Martin L., McDermott Tonya Maumus, Maytorena Hector, EASTMAN BRAD, and Davis Charles Louis IV, Traupman Edward, Slaughter Mark B., Smith Gail P, Gutierrez Gerry, OLSEN KEITH, Hagland Hansen Morten, Whittington Brent, de Vibe Ditlef, Mulloy Kevin C., OHARA KEVIN J, Schneider Charles E., Sutton William D., .

Insider Roster

Insider Dir Off 10% Shares Owned
Carter Benjamin Andrew Interim PAO
X 5,600
McDermott Tonya Maumus Interim CFO
X 19,437
OHARA KEVIN J Director
X 39,913
de Vibe Ditlef Director
X 23,218
OLSEN KEITH Director
X 21,187
Mulloy Kevin C. Director
X 9,207
Browning James H Director
X 31,428
Davis Charles Louis IV
25,111
Whittington Brent Director
X 33,828
Smith Gail P Director
X
Traupman Edward Vice President - SI&A
X 9,644
HILBERT JAY T SVP - Sales
X 7,470
PICKETT STEVEN EDWARD Chief Executive Officer, Director
X X 35,698
Sullivan Brendan CTO/CIO
X
EASTMAN BRAD Senior VP & General Counsel
X
Schneider Charles E. CFO and Senior Vice President
X 8,032
Sutton William D. Vice President
X 20,347
Jimmerson Martin L. Interim CEO and President
X
Gutierrez Gerry Group VP - TSI
X
Hagland Hansen Morten VP - Business Services
X
Maytorena Hector Vice President
X
Slaughter Mark B. Chief Executive Officer & Pres
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-15 4 McDermott Tonya Maumus F D 12.75 -346 19,437
2018-05-15 4 Carter Benjamin Andrew F D 12.75 -57 5,600
2018-05-15 4 Davis Charles Louis IV M D 4,798 25,111
2018-05-15 4 Browning James H M D 4,798 31,428
2018-05-15 4 Mulloy Kevin C. M D 4,798 9,207
2018-05-15 4 OLSEN KEITH M D 4,798 21,187
2018-05-15 4 de Vibe Ditlef M D 4,798 23,218
2018-05-15 4 OHARA KEVIN J M D 4,798 39,913
2018-05-15 4 Whittington Brent M D 4,798 33,828
2018-03-28 4 Davis Charles Louis IV S D 13.3123 -8,000 20,313 270,413
2018-03-27 4 Davis Charles Louis IV S D 13.7315 -4,000 28,313 388,780
2018-03-19 4 Mulloy Kevin C. S D 13.2119 -3,300 4,409 58,251
2018-03-19 4 PICKETT STEVEN EDWARD F D 13.40 -1,361 35,698
2018-03-19 4 McDermott Tonya Maumus F D 13.40 -1,508 19,783
2018-03-19 4 Carter Benjamin Andrew F D 13.40 -270 5,657
2018-03-19 4 HILBERT JAY T F D 13.40 -469 7,470
2018-03-19 4 Traupman Edward F D 13.40 -318 9,644
2018-03-19 4 PICKETT STEVEN EDWARD M D 3,101 37,059
2018-03-19 4 HILBERT JAY T M D 1,582 7,939
2018-03-19 4 Traupman Edward M D 1,074 9,962
2018-03-19 4 McDermott Tonya Maumus M D 3,380 21,291
2018-03-19 4 Carter Benjamin Andrew M D 915 5,927
2018-03-19 4 Davis Charles Louis IV S D 13.5106 -8,000 32,313 436,568
2018-02-28 4 PICKETT STEVEN EDWARD A D 30,029 33,958
2018-02-28 4 HILBERT JAY T A D 4,977 6,357
2018-02-28 4 Sullivan Brendan A D 5,809 5,809
2018-02-28 4 Carter Benjamin Andrew A D 2,844 5,012
2018-02-28 4 McDermott Tonya Maumus A D 5,596 17,911
2018-02-28 4 Traupman Edward A D 7,152 8,888
2017-12-27 4 Schneider Charles E. M D 6,667 8,032
2017-12-27 4 Schneider Charles E. M D 541 1,365
2017-12-27 4 Schneider Charles E. J D -3,361 824
2017-11-07 4 HILBERT JAY T F D 15.40 -495 1,380
2017-11-07 4 HILBERT JAY T M D 15.40 1,875 1,875
2017-11-07 4 Traupman Edward F D 15.40 -264 1,736
2017-11-07 4 Traupman Edward M D 15.40 1,000 2,000
2017-09-06 4 Davis Charles Louis IV S D 16.2517 -3,000 40,313 655,155
2017-05-27 4 PICKETT STEVEN EDWARD M D 3,929 3,929
2017-05-30 4 Schneider Charles E. F D 17.95 -296 4,185
2017-05-31 4 Sutton William D. F D 17.95 -506 20,347
2017-05-25 4 Sutton William D. F D 19.05 -464 20,853
2017-05-24 4 Davis Charles Louis IV S D 16.87 -1,750 43,313 730,690
2017-05-18 4 OLSEN KEITH M D 7,657 16,389
2017-05-18 4 Whittington Brent M D 7,657 29,030
2017-05-18 4 Browning James H M D 7,657 24,630
2017-05-18 4 Davis Charles Louis IV M D 7,657 45,063
2017-05-18 4 de Vibe Ditlef M D 7,657 18,420
2017-05-18 4 Mulloy Kevin C. M D 7,657 7,709
2017-05-18 4 OHARA KEVIN J M D 19,142 35,115
2017-03-28 4 Davis Charles Louis IV S D 19.85 -1,500 37,406 742,509
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

RigNet's (RNET) CEO Steven Pickett on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Ladies and gentlemen, welcome to RigNet's first quarter 2018 earnings conference call. My name is Skylar and I'll be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session after the prepared remarks by management. (28-0)

BRIEF-Rignet Announces Acquisitions In Energy Sector

2018-04-18 reuters
* RIGNET INC - ACQUIRED AUTOMATION COMMUNICATIONS ENGINEERING CORP AND SAFETY CONTROLS, INC Source text for Eikon: Further company coverage:

RigNet's (RNET) CEO Steven Pickett on Q4 2017 Results - Earnings Call Transcript

2018-03-07 seekingalpha
Ladies and gentlemen, welcome to RigNet’s Fourth Quarter and Full Year 2017 Earnings Conference Call. My name is Carrie and I will be you coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session after the prepared remarks by management. (28-0)

BRIEF-Rignet Says On Feb. 21 Co Appointed Tonya McDermott As Interim CFO

2018-02-26 reuters
* RIGNET INC SAYS ON FEBRUARY 21, 2018, COMPANY APPOINTED TONYA MCDERMOTT AS ITS INTERIM CHIEF FINANCIAL OFFICER - SEC FILING

BRIEF-RigNet Inc Senior VP and CFO Charles Schneider Will Leave Co

2017-12-21 reuters
* RIGNET INC - CHARLES E. (CHIP) SCHNEIDER, SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER (CFO), WILL LEAVE COMPANY Source text for Eikon: Further company coverage: